AllDocs -> cancers

bladder cancer BLADDER CANCER DIAGNOSTIC AND TREATMENT PATHWAY Gold Standard Timescale Emergency Presentation A&E AP Key Referral to GP Non urgent Emergency Information Flow Patient Flow AP Audited Protocols Primary Care Secondary Care (UNIT) ...

THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER THROUGH THE USE OF REPEAT T.U.R. – THE EXPERIENCE OF A PERIPHERAL CENTER J. Itovitch, V. Chouinard Centre Hospitalier Régional du Suroît, Salaberry-de-Valleyfield, Québec The standard treatment for muscle invasive bladder cancer is radical cystectomy. There is some evidence suggesting that in a select patient population, TUR alone may be sufficient treatment for their muscle invasive cancer . Since 1998, patients diagnosed with muscle invasive bladder cancer have been offered the potential bladder sparing treatment of repeat TUR. If all muscle invasive disease was eradicated, patients were treated with intravesicle BCG. Patients would then be followed with repeat metastatic evaluations as well as repeat cystoscopic and cytological examinations. A single pathologist confirmed all diagnoses. Seventeen patients diagnosed with muscle invasive ...

RISK FACTORS FOR BLADDER CANCER RECURRENCE FOLLOWING UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT Brant A Inman, Viet-Tan Tran, Yves Fradet, Louis Lacombe Division of Urology, Laval University, Québec, Canada Introduction: Relatively few groups have reported on the long-term incidence of bladder tumors following the surgical resection of carcinomas of the renal pelvis and ureter. Even fewer groups have attempted to identify risk factors predicting these recurrences. Methods: We retrospectively reviewed all cases of upper urinary tract malignancy treated at our center from 1978 to 2001. 168 patients were identified: 86 had renal pelvic tumors, 60 had ureteral tumors, and 22 had both renal pelvic and ureteral tumors. Mean age was 69.8 years and mean follow-up was 3.96 years. 39 (23%) patients had a preoperative history of bladder cancer : 29 (74%) were superficial, 5 (13%) were ...

GU SPORE Seminar Series for Patients with Bladder Cancer : “The Worlds of Patient “The Worlds of Patient Advocacy” Advocacy” Deborah E. Deborah E. Collyar Collyar President, Patient Advocates in Research (PAIR) President, Patient Advocates in Research (PAIR) The University of California San Francisco The University of California San Francisco THURSDAY, June 5, 2003 THURSDAY, June 5, 2003 6:00pm 6:00pm – – 8:00pm 8:00pm Location: Hospital Rose Zone Location: Hospital Rose Zone 11 11 th th Floor, R11.1100 Rooms 5,6 Floor, R11.1100 Rooms 5,6 M. D. ANDERSON CANCER CENTER M. D. ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD. 1515 HOLCOMBE BLVD. ...

14.1. INTRODUCTION AND SUMMARY Table 14.1. Summary of incidence and mortality statistics: bladder cancer INCIDENT CASES DEATHS males females both sexes males females both sexes All cancers (invasive, in situ and uncertain) (ICD-O-2 C67) 1997 cases 345 129 474 115 62 177 % of all cancers 3.3% 1.2% 2.2% 2.9% 1.8% 2.3% Incidence and mortality rates (per 100,000 persons per year) crude rate 19.1 7.0 13.0 6.4 3.4 4.9 World age-standardised rate 14.4 4.7 4.2 1.8 European age-standardised rate 22.4 6.7 7.2 2.8 cumulative risk (0-74) 1.6% 0.6% 0.4% 0.2% mortality/incidence ratio 0.333 0.481 0.373 Time trends (all cancers) 1994 cases 353 175 528 115 71 186 ...

Eur Urol 1992;21(suppl 2):7-11 F. Pagano P. Bassi C. Milani N. Piazza A. Meneghini A. Garbeglio BCG in Superficial Bladder Cancer : A Review of Phase III European Trials Istituto di Urologia, Universith degli Studi, Monoblocco Ospedaliero, Padova, Italy Key Words Abstract BCG Shortly after Morales’ original report, several phase II trials confirmed the effec- Superficial bladder cancer tiveness of intravesical bacillus Calmette-Guérin (BCG) in superficial bladder Phase III trials cancer therapy. Concerns have been expressed about the toxicity related to this Review new therapeutic modality. These phase II trial data led European urologists to try to answer some questions related to BCG therapy, such as the optimal schedule and dose, the most effective BCG strain and the value of BCG com- ...

In: Genes, Dogs and Cancer : 3rd Annual Canine Cancer Conference - 2003 , J. F. Modiano (Ed.) Publisher: International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA. Clinical Trials in Urinary Bladder Cancer – Translation from Dogs to Humans (5-Sep- 2003) D. Knapp 1 , S. I. Mohammed 2 , R. S. Foster 3 , L. Cheng 4 and W. R. Widmer 5 1,5 Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN, USA. 2 Department of Veterinary Pathobiology, Purdue University, West Lafayette, IN, USA. 3 Department of Urology, Indiana University, Indianapolis, IN, USA. 4 Department of Pathology, Indiana University, Indianapolis, IN, USA. Cancer is a major cause of morbidity and mortality in pet dogs and humans. Approximately ...

375 Early detection of bladder cancer in hematuria patients: Vision becomes reality P. Oehr , University Bonn, Germany. Conclusions The superior sensitivity of NMP22-BladderChek® over cytology, at the specificity of 98%, and the negative predictive value of 98%, give reason to call it an easy to handle cancer screening assay. Combined use with cytology can result in a highly reliable screening: under the condition "both test are positive", no false positive results arose, making this assumption a 100% tumor inclusion criterion in 67% of the patients who had developed a yet undetected urinary bladder cancer . In addition, a negative predictive value of 98% for NMP22-BladderChek® is an excellent exclusion criterion. Independently, NMP22-BladderChek® can detect 82% to 86% urinary bladder ...

bladder cancer Interim report Northern Western Regional Cancer Registry Centre for Cancer Epidemiology A.M. Sowerbutts & Dr. A. Moran Why have women with bladder cancer a worse prognosis than men Background Bladder cancer is the only common cancer for which women have a worse survival than men (Micheli et al 1998) Relative survival in Greater Manchester and Lancashire patients diagnosed in 1998 Age standardised relative survival by sex EXPLANATIONS Later stage at diagnosis Delay in diagnosis in women Difference natural history Difference in management METHODS North Western Cancer Registry Diagnosed ...

4 6 4 Annals Academy of Medicine NAT2 Phenotype in Painters—K Golka et al N-acetyltransferase 2 Phenotype in Painters with Bladder Cancer and Controls K Golka,* MD , W Weistenhöfer,** MD , P Jedrusik,** MD , F Geller,*** MSc , M Blaszkewicz, + PhD , H M Bolt, ++ MD, PhD Abstract Aim: This study was designed to evaluate the impact of N-acetyltransferase 2 (NAT2, substrate: aromatic amines) in painters with bladder cancer and controls. Background: Until the beginning of the 1960s, painters in Germany have used, among others, azo dyes based on carcinogenic aromatic amines. Materials and Methods: Sixteen painters with bladder cancer and 26 healthy painters (controls) who were from the same areas in Germany and in the same age group (± 5 years) ...

NOTE: Because of the uncertainty in interpreting the language used by pathologists to describe the extent of invasion, in situ bladder cancers are combined with invasive bladder cancers and are included in the total for all invasive cancer sites combined. The highest average annual age-adjusted incidence rate for urinary bladder cancer during the 1996-2000 period was among white males (44.6 per 100,000) - compared to 21.8 for black males and 11.4 for all females. In 2000, there were 3,602 new cases of urinary bladder cancer diagnosed among Pennsylvania residents for an age-adjusted rate of 24.7 per 100,000. This is the second highest annual number recorded during the 1991-2000 period. The annual age-adjusted incidence rates from 1991 to 2000 have been slightly increasing among white and black males and there were no discernible trends among white and black females. Over 83 percent of bladder cancer cases ...

X. Statistical Tables 96 Oregon State Cancer Registry Average Percent Average Percent Invasive Age Annual Malignant Age Annual Cases Adjusted Trend Deaths Adjusted Trend OREGON COUNTY INCIDENCE MORTALITY Per Year 1 Rate (APC) Per Year Rate (APC) 1996 - 2000 Rates are per 100,000 and age-adjusted to the 2000 U.S. (5-year groups) standard. * Trend is statistically stable. 1 Counts may not match state tables due to cases in unknown counties. ^ Rate not calculated due to instability of small numbers. APC = Average Annual Percent Change DATA Table 3j: Urinary Bladder Cancer State of Oregon 804 23.7 0.0 160 4.7 0.6 Baker ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com * Findings were statistically significant (strong evidence) + Evidence of a dose-response relationship (strongest evidence) Page 13 Bladder Cancer and Exposure to Ionizing Radiation Summary: There is strong evidence that bladder cancer may be associated with exposure to ionizing radiation. This evidence includes studies of nuclear workers. This is consistent with the National Research Council’s finding that the bladder is sensitive to ionizing radiation. Bladder cancer is designated as a “specified” cancer under the Energy Employees Occupational Illness Compensation Program Act. Historically, incidence of bladder cancer has been high in both Los Alamos County and Rio Arriba County. ...

Bladder Cancer Treatment Guidelines for Patients Version II / March 2003 Page 2 The mutual goal of the National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) partnership is to provide patients and the general public with state-of-the-art cancer treatment information in understandable language. This information, based on the NCCN’s Clinical Practice Guidelines, is intended to assist you in the dialogue with your doctor. These guidelines do not replace the expertise and clinical judgment of your doctor. Each patient’s situation must be evaluated individually. It is important to discuss the guidelines and all information regarding treatment options with your doctor. To ensure that you have the most up-to-date version of the guidelines, consult the Web sites of the ACS (www. cancer .org) or NCCN (www.nccn.org). You may also call ...

Asian Pacific Journal of Cancer Prevention Vol 1. 2000 15 Urinary Bladder Cancer : Experimental and Human Interface REVIEW Prevention of Urinary Bladder Cancer : The Interface Between Experimental and Human Studies Shoji Fukushima, Hideki Wanibuchi Abstract 1. Introduction: Bladder Cancer and the Environment Historical Aspects 2. Geographical Variation in Histopathological Types of Bladder Cancer Schistosomiasis Arsenic Poisoning Chernobyl 3. Analytical Epidemiological and Linked Experimental Findings Smoking Analgesic Abuse Saccharine 4. Histogenesis of Bladder Cancers Histopathology Molecular pathology 5. Carcinogens and Modification of Tumour Development Carcinogens Promoting agents Inhibitory agents 6. Prevention of Bladder Cancer Primary Prevention/ ...

Null Results in Brief No Association between Toenail Selenium Levels and Bladder Cancer Risk 1 Dominique S. Michaud, 2 Terryl J. Hartman, Philip R. Taylor, Pirjo Pietinen, Georg Alfthan, Jarmo Virtamo, and Demetrius Albanes Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics [D. S. M., D. A.] and Center for Cancer Research [T. J. H., P. R. T.], National Cancer Institute, Rockville, Maryland 20852; Pennsylvania State University, University Park, Pennsylvania 16802 [T. J. H.]; and Department of Epidemiology and Health Promotion, National Public Health Issue, Helsinki, Finland [P. P., G. A., J. V.] Introduction Geographic variations in bladder cancer risk, observed in the United States and other countries, have been ecologically re- lated to soil selenium levels. Evidence from clinical trials, ...

R EVIEW A Meta-Analysis of Bladder Cancer and Diesel Exhaust Exposure Paolo Boffetta 1,2 Debra T. Silverman 2 The aim of this study is to review and summarize the available epidemiologic studies of bladder cancer and occupational ex- posure to diesel exhaust. We retrieved relevant studies and abstracted their characteristics and results. We assessed the heterogeneity of the results to decide whether to perform a fixed-effects model meta-analysis. We identified 35 relevant studies. No overall meta-analysis was performed because of heterogeneity in results. Results of railroad workers (N 14) suggested an increased occurrence of bladder cancer , but we did not conduct a meta-analysis. The summary relative risk (RR) among truck drivers was 1.17 (95% confidence interval [CI] 1.06 –1.29, 15 studies) and that among bus ...

Bladder cancer and drinking water: a population-based case-control study in Washington County, Maryland (United States) Cancer Causes and Control. Vol 8. 1997 D. Michal Freedman, Kenneth P. Cantor, Nora L. Lee, Li-Shiun Chen, Hsien-Hsien Lei, Constance E. Ruhl, and Sophia S. Wang (Received 17 December 1996; accepted in revised form 7 April 1997) A population-based case-control study was conducted in Washington County, Maryland (United States) to explore the association between incident bladder cancer and exposure to drinking water from chlorinated surface sources. Cancer cases were White residents, enumerated in a 1975 county census and reported to the Washington County Cancer Registry ( n = 294) between 1975 and 1992. White controls, frequency matched by age (± 5 years) and gender, were selected randomly from the census ( n = 2,326). Households receiving ...

Cigarette Smoking, N -Acetyltransferase 2 Acetylation Status, and Bladder Cancer Risk: A Case-Series Meta-analysis of a Gene-Environment Interaction Pamela M. Marcus, Richard B. Hayes, Paolo Vineis, Montserrat Garcia-Closas, Neil E. Caporaso, Herman Autrup, Robert A. Branch, Ju ¨ rgen Brockmo¨ller, Takashi Ishizaki, Ali Esat Karakaya, Jose M. Ladero, Soren Mommsen, Henrik Okkels, Marjorie Romkes, Ivar Roots, and Nathaniel Rothman 1 Divisions of Cancer Prevention [P. M. M.] and Cancer Epidemiology and Genetics [R. B. H., M. G-C., N. E. C., N. R.]; National Cancer Institute, Bethesda, Maryland 20892; Department of Environmental and Occupational Medicine, University of Aarhus, Aarhus, Denmark DK-8000 [H. A., H. O.]; Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 [R. A. B., M. R.]; Department of Clinical Pharmacology ...

Nitrate in Public Water Supplies and Risk of Bladder Cancer Mary H. Ward, 1 Kenneth P. Cantor, 1 David Riley, 2 Shannon Merkle, 3 and Charles F. Lynch 4 Background. Nitrate is a precursor compound in the formation of N-nitroso compounds, most of which are potent animal carcinogens. N-nitroso compounds and their precursors have not been extensively evaluated as bladder cancer risk factors. Methods. We conducted a population-based case-control study of bladder cancer in Iowa. Cases were men and women newly diagnosed with bladder cancer in 1986 –1989. Nitrate data for Iowa public water supplies were sparse before the 1960s. To reduce misclassification by unknown nitrate lev- els, we included only those who used public supplies with nitrate data for 70% or more of their person-years ...

Arsenic-Related Chromosomal Alterations in Bladder Cancer Lee E. Moore, Allan H. Smith, Clarence Eng, David Kalman, Sandy DeVries, Vivek Bhargava, Karen Chew, Dan Moore II, Catterina Ferreccio, Omar A. Rey, Frederic M. Waldman Background: Previous studies have demonstrated that inges- tion of arsenic in drinking water is a strong risk factor for several forms of cancer , including bladder cancer . It is not known whether arsenic-related cancers are genetically simi- lar to cancers in unexposed individuals or what mechanisms of carcinogenesis may underlie their formation. This study was designed to compare chromosomal alterations in blad- der cancers of arsenic-exposed individuals to provide insight into the mechanism of how arsenic may induce or promote cancer . Methods: A case–case study was conducted in Ar- gentina and Chile examining ...

Current Smoking, Occupation, N -Acetyltransferase-2 and Bladder Cancer : A Pooled Analysis of Genotype-based Studies Paolo Vineis, Daniela Marinelli, Herman Autrup, Jurgen Brockmoller, Ingolf Cascorbi, Ann K. Daly, Klaus Golka, Henry Okkels, Angela Risch, Nathalien Rothman, Edith Sim, and Emanuela Taioli 1 CPO-Piemonte at the University of Torino, via Santena 7 and Institute for Scientific Interchange Foundation, I-10126 Torino, Italy [P. V.]; Ospedale Policlinico IRCCS and University of Milan, 20122 Milan, Italy [D. M., E. T.]; University of Aarhus, Arhus C, DK-8000 Denmark [H. A., H. O.]; University of Berlin, Berlin, D-10098 Germany [J. B.]; Ernst Moritz Arndt University, Greifswald, D-17487 Germany [I. C.]; University of Newcastle, Newcastle- upon-Tyne, NE2 4HH United Kingdom [A. K. D.]; Institut fur Arbeitsphysiologie, Dortmund, D-44139 Germany [K. G.]; Deutsches Kr...

Bladder and Kidney Cancer Following Cyclophosphamide Therapy Non-Hodgkin’s Lymphoma for Lois B. Travis, Rochelle E. Curtis, Bengt Glimelius, Eric J. Holowaty, Flora E. Van Leeuwen, Charles F. Lynch, Anton Hagenbeek, Marilyn Stovall, Peter M. Banks, Johanna Adami, Mary K. Gospodarowicz, Sholom Wacholder, Peter D. Inskip, Margaret A. Tucker, John D. Boice, Jr.* Background: Cyclophosphamide is an established bladder carcinogen, but few studies have examined the relationship between dose and effect. The largest analysis to date in- cluded only seven cases of bladder cancer . No investigation has estimated the risk of kidney cancer . Purpose: The pur- pose of this study was to quantify the risk of bladder and kidney cancer following cyclophosphamide therapy. Methods: Within a cohort of 6171 two-year survivors of non- Hodgkin’s ...

TRENDS IN MORTALITY FROM BLADDER CANCER (ICD9 188): INDIRECTLY STANDARDISED RATIOS (SMR ), 1989 TO 1999 ANNUALLY, ALL AGES (Standard rates are age-specific mortality rates in 1993) ----------------------------- ------ ------- ------- -------- -------- -------- -------- -------- ------- -------- ------- -------- - -------- ------- -------- -------- -------- -------- ------- -------- ------- ------- -------- Males Females 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 ENGLAND AND WALES SMR 104 106 106 110 100 97 98 93 89 86 82 105 106 101 104 100 104 99 95 96 94 92 OBS 3165 3290 3327 3476 3211 3139 3242 3105 3016 2966 2845 1572 1600 1544 1611 1555 1619 1552 1501 1522 1498 1459 LONDON SMR 118 123 114 117 93 88 101 ...

Bladder Cancer INTRODUCTION Cancer of the bladder is the fourth most common cancer among men and the ninth most common cancer among women. About 39,500 men and 14,900 women will develop bladder cancer this year. Bladder cancer is the fourth leading cause of cancer and the seventh leading cause of cancer death. Cancer of the bladder may occur at any age, but it usually strikes those over 50 years old. If detected and treated early, bladder cancer is almost always cured (the 5-year survival rate of early bladder cancer is 90%). Unfortunately, less than one in ten patients with metastatic bladder cancer survive five or more years (metastatic means the cancer has spread to other areas such as lymph nodes, bones, lung, etc). Each year about 6,000 men and 3,000 women will die of the disease. During the past 30 years, the death ...

RESOURCE SUPPORT For additional information about bladder cancer , the following resources are available: National Cancer Institute Cancer Information Service (CIS) 1-800-4- CANCER Cancernet www.cancernet.nci.nih.gov The Cancer Information Service (CIS) and Cancernet are National Cancer Institute programs that provide a nationwide telephone service and web site for cancer patients, their families and friends. American Cancer Society 1-800-ACS-2345 www. cancer .org The American Cancer Society (ACS) is a voluntary organization with a national office in Atlanta, Georgia, and local facilities across the country. It supports research, patient education programs, and other services for family members. It also publishes and distributes free booklets on colon cancer and home care. AmeriPath, Inc. www.ameripath.com AmeriPath, Inc., is a ...

bladder cancer Bladder Cancer Last Updated: February 8, 2002 Rate this Article Email to a Colleague Synonyms and related keywords: urothelial cancer , transitional cell cancer , transitional cell carcinoma, TCC, bladder cancer , bladder tumor, leiomyosarcoma, rhabdomyosarcoma AUTHOR INFORMATION Section 1 of 11 Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography Author: Gary David Steinberg, MD , Director of Urology, Assistant Professor, Department of Surgery, Division of Urology, University of Chicago School of Medicine and Weiss Memorial Hospital Coauthor(s): Hyung ...

90 VOL. 5 NO. 2 2003 REVIEWS IN UROLOGY F ollowing is a review of note- worthy abstracts focusing on prostate cancer , bladder can- cer, renal cell cancer , and benign prostatic hyperplasia, that were pre- sented at the XVIIth Congress of the European Association of Urology. Prostate Cancer Prostate-Specific Antigen and Derivatives Ulmert and colleagues 1 studied archival material regarding aspects of stability and grade of degradation in free prostate-specific antigen (fPSA) and total prostate-specific antigen (tPSA) in serum and ethyl- enediaminetetraacetic acid (EDTA)- plasma samples that had been stored for 25 years at 20ºC. A total of 126 serum and 98 EDTA-plasma samples were randomly selected from a popu- lation study that included 22,439 men. Patients diagnosed with prostate cancer ...

17 May 2003 No. 53 H I G H L I G H T S Incorporating molecular profiling in bladder cancer 3 Oral zebularine reactivates silenced genes 5 Thalidomide increases risk of VTE in patients receiving docetaxel 6 CONTENTS Antineoplastics (dose-intensified) in breast cancer 3 Antineoplastics frequently used in the last months of life 6 ASCO guidelines "well received" in the US 6 Bladder cancer : incorporating molecular profiling 3 Carmustine polifeprosan 20 wafer in glioma 4 Cladribine: beneficial long-term results in hairy cell leukaemia 4 Efaproxiral: survival benefit in brain metastases 5 Imatinib mesylate in CML: surpassing its success 2 Immunotherapy eradicates cancer in mice 5 Impact of EU directive on clinical research 3 Mitomycin: metallothionein ...